Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001144204-11-056106
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-10-03 18:42:39
Reporting Period:
2011-09-29
Filing Date:
2011-10-03
Accepted Time:
2011-10-03 18:42:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
946840 Viropharma Inc VPHM Pharmaceutical Preparations (2834) 232789550
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1087939 Julian Baker 667 Madison Avenue, 21St Floor
New York NY US 10065
No No Yes No
1087940 Felix Baker 667 Madison Avenue, 21St Floor
New York NY US 10065
No No Yes No
1307729 Baker Brothers Life Sciences Capital (Gp), Llc 667 Madison Avenue, 21St Floor
New York NY US 10065
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-09-29 89,970 $17.97 8,549,290 No 4 P Indirect Through Partnership
Common Stock Acquisiton 2011-09-29 159,945 $18.00 8,709,235 No 4 P Indirect Through Partnership
Common Stock Acquisiton 2011-09-30 43,321 $18.19 8,752,556 No 4 P Indirect Through Partnership
Common Stock Acquisiton 2011-09-30 88,657 $18.08 8,841,213 No 4 P Indirect Through Partnership
Common Stock Acquisiton 2011-10-03 70,629 $17.62 8,911,842 No 4 P Indirect Through Partnership
Common Stock Acquisiton 2011-10-03 445,574 $17.71 9,357,416 No 4 P Indirect Through Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Through Partnership
No 4 P Indirect Through Partnership
No 4 P Indirect Through Partnership
No 4 P Indirect Through Partnership
No 4 P Indirect Through Partnership
No 4 P Indirect Through Partnership
Footnotes
  1. In addition to Baker Brothers Life Sciences Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Brothers Life Sciences Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (Continued in footnote 2).
  2. However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
  3. Represents securities owned directly by Baker Brothers Life Sciences, L.P., the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP),LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.